N-Phenyl-2-indolinones and N-Pheny lindo lines. a New Class of Antidepressant Agents†

Journal of Medicinal Chemistry

Volumn 15, Issue 7, 1972, Pages 762-770

  Canas Rodriguez A ^a   Leeming, P R ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANILINE DERIVATIVE; ANTIDEPRESSANT AGENT; INDOLE DERIVATIVE; NORADRENALIN; RESERPINE; TETRABENAZINE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; CAT; CRYOANESTHESIA; DRUG EFFECT; DRUG POTENTIATION; MALE; MOUSE; NICTITATING MEMBRANE; PREGANGLIONIC NERVE; RAT; STIMULATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMPHETAMINE; ANILINE COMPOUNDS; ANIMAL; ANTIDEPRESSIVE AGENTS; AUTONOMIC FIBERS, PREGANGLIONIC; BEHAVIOR, ANIMAL; CATS; DRUG SYNERGISM; HYPOTHERMIA, INDUCED; INDOLES; MALE; MICE; NICTITATING MEMBRANE; NOREPINEPHRINE; RATS; RESERPINE; STIMULATION, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; TETRABENAZINE;

EID: 0015367526     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00277a017     Document Type: Article

References (42)

1. A. Cañas-Rodriguez and P. R. Leeming, Nature (London), 223, 75 (1969);
2. Pfizer British Patent 1, 154, 976 (1969);
3. application filed Feb 21, 1967;
4. S. Toyoshima, W. Hirose, K. Yamatsu, and S. Sohda, Yakugaku Zasshi, 90, 1524 (1970).
5. J. H. Biel, “Drugs Affecting the Central Nervous System,” Vol. 2, A. Burger, Ed., Arnold, London, 1968, p 61.
6. F. Sulser, M. H. Bickel, and B. B. Brodie, J. Pharmacol. Exp. Ther., 144, 321 (1964);
7. K. D. Cairncross, S. Gershon, and I. D. Gust, J. Neuropsychiat., 4, 224 (1963).
8. D. F. Bogdanski, F. Sulser, and B. B. Brodie, J. Pharmacol. Exp. Ther., 132, 176 (1961).
9. E. Costa, S. Garratini, and L. Valzelli, Experientia, 16, 461 (1960),
10. R. Domenajoz and W. Theobald, Arch. Int. Pharmacodyn., 21, 450 (1959).
11. R. C. Rathbun and I. H. Slatter, Psychopharmacologia, 4, 114 (1963).
12. B. Smith and D. J. Prockop, N. Engl. J. Med., 267, 1338 (1962).
13. A. Coppen, D. M. Shaw, and J. P. Farrel, Lancet, 1, 79 (1963).
14. C. M. B. Pare, Lancet, 2, 527 (1963).
15. A. Coppen, D. M. Shaw, B. Berzberg, and R. Maggs, Lancet, 2, 1178 (1967).
16. B. B. Brodie and P. A. Shore, Ann. N. Y. Acad. Sci., 66, 631 (1957).
17. N. J. Giarman, Yale J. Biol. Med., 32, 73 (1959).
18. M. Vogt, J. Physiol, 123, 451 (1954).
19. T. B. B. Crawford, “5-Hydroxytryptamine: Proceedings of a Symposium”, G. P. Lewis, Ed., Pergamon, New York, N.Y., 1958, pp 20-25.
20. G. G. Bruñe and H. E. Himwich, Recent Advan. Biol. Psychiat., 5, 144 (1963).
21. J. Crossland, West Ew. Symp. Clin. Chem., 2, 175 (1962).
22. N. A. Hillarp, K. Fuxe, and A. Dahlstrom, Pharmacol. Rev., 18, 727 (1966).
23. H. D. Fabing and J. R. Hawkins, Science, 123, 886 (1956).
24. P. V. Petersen and I. Møeller-Nielsen, Antidepressant Drugs. Pro Int. Symp. 1st, 1966, 217 (1967).
25. T. W. Kissel, Antidepressant Drugs. Pro Int. Symp. 1st, 233 (1967).
26. G. N. Walker, R. T. Smith, and B. N. Weaver, J. Med. Chem., 8, 626 (1965).
27. R. Stolle, Ber., 46, 3915 (1913);
28. A. Cañas-Rodriguez and J. R. Stichbury, paper in preparation.
29. P. L. Julian and J. Pikl, J. Amer. Chem. Soc, 57, 539 (1935).
30. F. Bickelhaupt, K. Stach, and M. Thiel, Monatsh., 95, 485 (1964).
31. James B. Hendrickson, Thesis, Harvard University, 1954.
32. K. Freter, H. Weissbach, B. Redfield, S. Udenfriend, and B. Witkop, J. Amer. Chem. Soc, 80, 983 (1958).
33. E. Wenkert, B. S. Bernstein, and J. H. Udelhofen, J. Amer. Chem. Soc, 80, 4899 (1958).
34. P. J. Islip and A. C. White, J. Chem. Soc, 120 (1964).
35. R. M. Quinton and G. Halliwell, Nature (London), 200, 178 (1963).
36. B. Askew, Life Sci., 2, 725 (1963).
37. G. Palazzo and V. Rosnatti, Gazz. Chim, Ital, 82, 584 (1952);
38. Chem. Abstr., 47, 12347 (1953).
39. M. E. Speeter, U. S. Patent 2, 759, 935 (1956);
40. Chem. Abstr., 51, 2050 (1957).
41. R. T. Brittain, J. Pharm. Pharmacol, 18, 621 (1966).
42. P. Cowell and M. J. Davey, Brit. J. Pharmacol. Chemother., 34, 159 (1968).